These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16648037)

  • 41. CHOP plus rituximab--balancing facts and opinion.
    Cheson BD
    N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
    [No Abstract]   [Full Text] [Related]  

  • 42. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.
    Dillman RO
    J Clin Oncol; 2002 Aug; 20(16):3545-57. PubMed ID: 12177115
    [No Abstract]   [Full Text] [Related]  

  • 43. [Treatment of diffuse large B-cell lymphoma].
    Gleissner B; Zwick C; Pfreundschuh M
    Dtsch Med Wochenschr; 2008 Sep; 133(36):1785-94; quiz 1795-6. PubMed ID: 18767006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Resistance to rituximab and CD20 mutation].
    Terui Y; Hatake K
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():416-23. PubMed ID: 17474440
    [No Abstract]   [Full Text] [Related]  

  • 45. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma.
    Eur J Cancer Care (Engl); 2003 Dec; 12(4):306-7. PubMed ID: 14982308
    [No Abstract]   [Full Text] [Related]  

  • 47. [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab].
    Kataoka T; Ishida Y; Kurokawa R; Takeshita S; Ohta K; Nishimura Y; Yokoyama M
    Nihon Kokyuki Gakkai Zasshi; 2003 Dec; 41(12):899-904. PubMed ID: 14727553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Diffue large B-cell lymphoma in a child treated by rituximab complicated with chemotherapy].
    Chang J; Wang LJ; Wang LZ; Zhang YT; Zhong XD
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 May; 14(5):387-8. PubMed ID: 22613114
    [No Abstract]   [Full Text] [Related]  

  • 50. Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein Barr virus-linked lymphoma.
    Sirvent-Von Bueltzingsloewen A; Sirvent N; Morand P; Cassuto JP
    Med Pediatr Oncol; 2003 Jun; 40(6):408-9. PubMed ID: 12692818
    [No Abstract]   [Full Text] [Related]  

  • 51. Regression of cutaneous intravascular lymphoma with rituximab.
    Han K; Haley JC; Carlson K; Pinter-Brown L; Soriano T
    Cutis; 2003 Aug; 72(2):137-40. PubMed ID: 12953938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complete molecular remission induced by rituximab in a patient with diffuse large cell lymphoma.
    Zinzani PL; Bendandi M; Gamberi B; Magagnoli M; Gherlinzoni F; Tura S
    Haematologica; 2000 Apr; 85(4):437-8. PubMed ID: 10756377
    [No Abstract]   [Full Text] [Related]  

  • 53. Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20.
    Abou Mourad Y; Taher A; Shamseddine A
    Hematol J; 2003; 4(3):222-4. PubMed ID: 12764356
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry.
    Krause SW; Gerken M; Andreesen R; Hofstädter F; Klinkhammer-Schalke M
    Ann Hematol; 2012 Apr; 91(4):561-70. PubMed ID: 22200972
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current status of rituximab maintenance therapy.
    Vose JM
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):968-9,1006. PubMed ID: 18277958
    [No Abstract]   [Full Text] [Related]  

  • 56. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Standard treatment of advanced-stage diffuse large B-cell lymphoma.
    Coiffier B
    Semin Hematol; 2006 Oct; 43(4):213-20. PubMed ID: 17027655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytomegalovirus enterocolitis in a patient with diffuse large B-cell lymphoma after chemotherapy with rituximab.
    Seewoodhary J
    World J Gastroenterol; 2006 Dec; 12(45):7391. PubMed ID: 17143963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Waxing and waning intravascular large cell lymphoma with widespread organ infiltration.
    Vos JM; Bordbar A; Vet RJ; Pals ST; Kater AP
    Leuk Lymphoma; 2011 Apr; 52(4):705-8. PubMed ID: 21190427
    [No Abstract]   [Full Text] [Related]  

  • 60. Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
    Cheah CY; Seymour JF
    Leuk Lymphoma; 2014 Mar; 55(3):471-3. PubMed ID: 23906017
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.